Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aim: To investigate the behavioural and intracellular mechanisms by which the glucagon like peptide‐1 ( GLP ‐1) receptor agonist, liraglutide, and leptin in combination enhance the food intake inhibitory and weight loss effects of either treatment alone. Methods: We examined the effects of liraglutide (a long‐acting GLP ‐1 analogue) and leptin co‐treatment, delivered in low or moderate doses subcutaneously (s.c.) or to the third ventricle, respectively, on cumulative intake, meal patterns and hypothalamic expression of intracellular signalling proteins [phosphorylated signal transducer and activator of transcription‐3 ( pSTAT3 ) and protein tyrosine phosphatase‐ 1B ( PTP1B )] in lean rats. Results: A low‐dose combination of liraglutide (25 µg/kg) and leptin (0.75 µg) additively reduced cumulative food intake and body weight, a result mediated predominantly through a significant reduction in meal frequency that was not present with either drug alone. Liraglutide treatment alone also reduced meal size; an effect not enhanced with leptin co‐administration. Moderate doses of liraglutide (75 µg/kg) and leptin (4 µg), examined separately, each reduced meal frequency, cumulative food intake and body weight; only liraglutide reduced meal size. In combination these doses did not further enhance the anorexigenic effects of either treatment alone. Ex vivo immunoblot analysis showed elevated pSTAT3 in the hypothalamic tissue after liraglutide‐leptin co‐treatment, an effect which was greater than that of leptin treatment alone. In addition, s.c. liraglutide reduced the expression of PTP1B (a negative regulator of leptin receptor signalling), revealing a potential mechanism for the enhanced pSTAT3 response after liraglutide‐leptin co‐administration. Conclusions: Collectively, these results show novel behavioural and molecular mechanisms underlying the additive reduction in food intake and body weight after liraglutide‐leptin combination treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Mechanisms of leptin action and leptin resistance.
Myers, M. G., Cowley, M. A., & Münzberg, H. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100707 · Cited by 1,074 · cited 1×
“The intake inhibitory effect of LepRb signalling is mediated, in part, via the JAK-STAT pathway, where leptin binds to LepRb and results in the phosphorylation of Janus kinase-2(pJAK2) and STAT3 (pSTAT3) [49].”
BackgroundThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 2×
“Further, both leptin [57] and peripherally-injected liraglutide [58] bind to proopiomelanocortin- and cocaine- and amphetamine-regulated transcript-expressing neurons in the”
BackgroundLeptin Receptor Signaling in Midbrain Dopamine Neurons Regulates Feeding
Hommel, J. D., Trinko, R., Sears, R. M., Georgescu, D., Liu, Z.-W., Gao, X.-B., Thurmon, J. J., Marinelli, M., & DiLeone, R. J. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.023 · Cited by 902
Neuronal PTP1B regulates body weight, adiposity and leptin action
Bence, K. K., Delibegovic, M., Xue, B., Gorgun, C. Z., Hotamisligil, G. S., Neel, B. G., & Kahn, B. B. (2006) · Nature Medicine · doi:10.1038/nm1435 · Cited by 633 · cited 1×
“Furthermore, PTP1B genetic deficiency and pharmacological inhibition of PTP1B is known to increase leptin sensitivity [53,54], highlighting the significance of PTP1B in energy balance control.”
BackgroundAlhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · cited 1×
“Given that acute liraglutide reduces food intake via activation of both peripheral and central GLP-1 receptors after peripheral administration [40,45], it is possible that the meal pattern effects observed in the present study are mediated by an action in the periphery, centrally, or both.”
BackgroundSelf-citationEvidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · cited 1×
“In rodents, peripheral exendin-4 reduces both meal size and meal frequency [19], whereas exendin-4 administration to the ventral tegmental area [20] or to the ventral hippocampus [21] reduces intake via a specific reduction in meal size.”
BackgroundKanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · cited 2×
“Doses were selected to be in the low to moderate range for food intake reduction based on dose–response curves for peripheral liraglutide [30] and ICV leptin [31].”
BackgroundSelf-citationHorowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · cited 1×
“The incretin hormone glucagon-like peptide-1 (GLP-1) is a promising target biological system for the pharmacological treatment of obesity [4,5].”
Background
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“The various approaches include the combination of GLP-1R agonists with leptin [912,913], salmon calcitonin [914], PYY [915], CCK [916], insulin [917], adrenomedullin [918], and b3-adrenergic receptor agonists [919], and antagonists at the cannabinoid receptor 1 (CB1) [920], or agonists at the receptors for melanocorti…”
BackgroundSelf-citationGLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
Self-citationLeptin, cardiovascular diseases and type 2 diabetes mellitus
Katsiki, N., Mikhailidis, D. P., & Banach, M. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.40 · Cited by 285
Leptin applications in 2015: what have we learned about leptin and obesity?
Farr, O. M., Gavrieli, A., & Mantzoros, C. S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000184 · Cited by 233
He, Z., Gao, Y., Lieu, L., Afrin, S., Cao, J., Michael, N. J., Dong, Y., Sun, J., Guo, H., & Williams, K. W. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.07.008 · Cited by 128
“This is in agreement with the ability of low dose GLP-1R agonists to potentiate the effects of leptin to suppress food intake and body weight [63,64].”
BackgroundResultHeiss, C. N., Mannerås-Holm, L., Lee, Y. S., Serrano-Lobo, J., Håkansson Gladh, A., Seeley, R. J., Drucker, D. J., Bäckhed, F., & Olofsson, L. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109163 · Cited by 114
Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102
“GLP-1 signaling pathways are known to interact with other hormonal systems such as leptin (Kanoski et al, 2015; Williams et al, 2006; Zhao et al, 2012), ghrelin (Chelikani et al, 2006), and amylin (Bello et al, 2010) to exert effects on food intake and energy balance control.”
BackgroundSelf-citationOkamoto, H., Kim, J., Aglione, J., Lee, J., Cavino, K., Na, E., Rafique, A., Kim, J. H., Harp, J., Valenzuela, D. M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1011 · Cited by 100
Fortin, S. M., Chen, J., & Hayes, M. R. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112870 · Cited by 10
Self-citation
Metadata
- Authors
- Kanoski, S. E., Ong, Z. Y., Fortin, S. M., Schlessinger, E. S., & Grill, H. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-01-08
- Volume
- 17
- Issue
- 3
- Pages
- 285-293
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2146727082
- Cited by
- 40
- References
- 13
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.